Tissue accumulation of cephalothin in burns: a comparative study by microdialysis of subcutaneous interstitial fluid cephalothin concentrations in burn patients and healthy volunteers.
Burn tissue sites are a potential source of bacteremia during debridement surgery. Burn injury is likely to affect the distribution of antibiotics to tissues, but direct evidence of this is lacking. The aim of this study was to directly evaluate the influence of burn trauma on the distribution of cephalothin to peripheral tissues. We used subcutaneous microdialysis techniques to monitor interstitial fluid concentrations of cephalothin in the burnt and nonburnt tissues of adult patients with severe burns following parenteral administration of 1 g cephalothin for surgical prophylaxis. Analogous simultaneous studies conducted with healthy adult volunteers provided reference tissue concentration data. Equivalent tissue exposures were seen for burn and nonburn sites, giving overall median interstitial cephalothin concentrations (from 0 to 240 min) of 2.84 mg/liter and 3.06 mg/liter, respectively. A lower overall median interstitial cephalothin concentration of 0.54 mg/liter was observed for healthy individuals, and the patient nonburnt tissue and volunteer control tissue cephalothin concentrations exhibited significantly different data distributions (P < 0.001; Kolmogorov-Smirnov nonparametric test). The duration of tissue residence for cephalothin was longer for burn patients than for healthy volunteers. The results demonstrate the potential fallibility of using healthy population models to extrapolate tissue pharmacodynamic predictions from plasma data for burn patients.
Dalley
Andrew J
AJ
Burns Trauma & Critical Care Research Centre, University of Queensland, Royal Brisbane & Women's Hospital, Brisbane, Queensland, Australia. a.dalley@uq.edu.au
Lipman
Jeffrey
J
Deans
Renae
R
Venkatesh
Bala
B
Rudd
Michael
M
Roberts
Michael S
MS
Cross
Sheree E
SE
D000328:Adult; D002056:Burns / Q000188:drug therapy*; D002512:Cephalothin / Q000032:analysis* / Q000493:pharmacokinetics* / Q000627:therapeutic use; D045604:Extracellular Fluid / Q000378:metabolism*; D006801:Humans; D017551:Microdialysis / Q000379:methods*; D040521:Subcutaneous Tissue / Q000378:metabolism*
D002512:Cephalothin